InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
February 11, 2021 07:30 ET
|
InflaRx N.V.
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patientsVilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction...
InflaRx Provides Update on Vilobelimab (IFX-1) Development
January 11, 2021 07:30 ET
|
InflaRx N.V.
Multiple data readouts expected in 2021Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 JENA, Germany, Jan. 11, 2021 (GLOBE...
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
January 07, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
January 05, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Q3 2020 Financial & Operating Results
October 29, 2020 07:00 ET
|
InflaRx N.V.
Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumoniaPublished encouraging data from Phase II part of COVID-19 trial in...
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
September 17, 2020 07:30 ET
|
InflaRx N.V.
Thomas Taapken, Ph.D. appointed Chief Financial OfficerJordan Zwick promoted to Chief Strategy Officer JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage...
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
September 14, 2020 07:30 ET
|
InflaRx N.V.
First site initiated for enrollment in the NetherlandsRegulatory approval granted to start trial in GermanyAdditional sites to be added in the US, EU and other regionsEncouraging Phase II data...
InflaRx to Present at Upcoming Virtual Investor Events
August 06, 2020 07:30 ET
|
InflaRx N.V.
JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Q2 2020 Financial & Operating Results
July 30, 2020 07:30 ET
|
InflaRx N.V.
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day...
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
July 21, 2020 07:30 ET
|
InflaRx N.V.
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory...